Sign up to save your podcasts
Or
Share Three Alternative CoVid Treatments Don’t Work
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Three Alternative CoVid Treatments Don’t Work
Vidcast: https://youtu.be/9yjeL3pYS-4
Metformin, ivermectin, and fluvoxamine, 3 drugs in current use for other conditions, offer no help when taken for CoVid infections in non-hospitalized patients. This the conclusion of a definitive doubled-blind, randomized, placebo-controlled collaborative study headed by researchers at the University of Minnesota.
A total of 1431 patients participated. Their median age was 46 years, 56% were female, 6% were pregnant, and 52% had been vaccinated. The data analysis showed that these 3 drugs, metformin, ivermectin, and fluvoxamine failed to prevent CoVid-driven lung infections with low blood oxygenation, ER visits, hospitalizations, or death.
If you do contract CoVid and are at risk for serious disease, know that there are effective agents to stop the virus from landing you in the hospital or in a coffin. Taken as soon as possible after a CoVid diagnosis, Paxlovid taken orally and remdesivir administered intravenously are viral polymerase inhibitors that block CoVid replication in those with early infections. For those with more severe and persistent infections, intravenously administered monoclonal antibodies that block viral entry into human cells as a group have less effectiveness against the current Omicron sub-variant BA.5. One monoclonal antibody, bebtelovimab, and the monoclonal antibody cocktail of 2 monoclonal antibodies, Evusheld, do work against BA.5 and can be used for outpatient and hospitalized CoVid patients.
https://www.nejm.org/doi/full/10.1056/NEJMoa2201662?query=TOC&cid=NEJM%20eToc,%20August%2018,%202022%20DM1352386_NEJM_Non_Subscriber&bid=1120617993
#covid #paxlovid #monoclonalantibodies #bebtelovimab #evusheld #ivermectin #metformin #fluvoxamine
View all episodes
By Howard G. Smith MD, AM
Vidcast: https://youtu.be/9yjeL3pYS-4
Metformin, ivermectin, and fluvoxamine, 3 drugs in current use for other conditions, offer no help when taken for CoVid infections in non-hospitalized patients. This the conclusion of a definitive doubled-blind, randomized, placebo-controlled collaborative study headed by researchers at the University of Minnesota.
A total of 1431 patients participated. Their median age was 46 years, 56% were female, 6% were pregnant, and 52% had been vaccinated. The data analysis showed that these 3 drugs, metformin, ivermectin, and fluvoxamine failed to prevent CoVid-driven lung infections with low blood oxygenation, ER visits, hospitalizations, or death.
If you do contract CoVid and are at risk for serious disease, know that there are effective agents to stop the virus from landing you in the hospital or in a coffin. Taken as soon as possible after a CoVid diagnosis, Paxlovid taken orally and remdesivir administered intravenously are viral polymerase inhibitors that block CoVid replication in those with early infections. For those with more severe and persistent infections, intravenously administered monoclonal antibodies that block viral entry into human cells as a group have less effectiveness against the current Omicron sub-variant BA.5. One monoclonal antibody, bebtelovimab, and the monoclonal antibody cocktail of 2 monoclonal antibodies, Evusheld, do work against BA.5 and can be used for outpatient and hospitalized CoVid patients.
https://www.nejm.org/doi/full/10.1056/NEJMoa2201662?query=TOC&cid=NEJM%20eToc,%20August%2018,%202022%20DM1352386_NEJM_Non_Subscriber&bid=1120617993
#covid #paxlovid #monoclonalantibodies #bebtelovimab #evusheld #ivermectin #metformin #fluvoxamine